Search clinical trials for: HDM201

Total 103 results

Novartis Pharmaceuticals

Terminated

A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.

Uveal Melanoma

United States, Australia, France, Netherlands, Spain, Norway
Novartis Pharmaceuticals

Terminated

A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant

Acute Myeloid Leukemia | Allogeneic Stem Cell Transplantation

Italy, Germany, Spain
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma

Liposarcoma

France, Taiwan, Germany, Spain, Canada, Singapore
Novartis Pharmaceuticals

Completed

Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt

Advanced Solid and Hematological TP53wt Tumors

France, Netherlands, Spain, Germany, Singapore, Japan, Taiwan, United States
Centre Leon Berard
Novartis; National Cancer Institute, France

Recruiting

HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas (AMPHISARC)

Advanced Soft-tissue Sarcoma | Metastatic Soft-tissue Sarcoma

France
Novartis Pharmaceuticals

Active, not recruiting

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients (ADORE)

Myelofibrosis

United Kingdom, Australia, Canada, Switzerland, Netherlands, Spain, Germany, Italy, Turkey, Russian Federation, Sweden, Denmark, Hungary
IlDong Pharmaceutical Co Ltd

Completed

Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease

Alzheimer Disease

Korea, Republic of
Novartis Pharmaceuticals

Active, not recruiting

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)

Spain, Singapore, Australia, Germany, Italy, Finland, United States
Almac Discovery

Terminated

A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours

Ovarian Cancer | Solid Tumors

United Kingdom
Centre Leon Berard
Novartis

Completed

Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (TRAHD)

Colorectal Cancer | Metastatic Cancer | Advanced Cancer

France
InnoBM Pharmaceuticals Co., Ltd.

Recruiting

BM201 in Combination With Radiotherapy in Patients With Advanced Solid Tumors (BM201-1001)

Advanced Solid Tumors

China
Jetema USA Inc.

Not yet recruiting

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

Glabellar Lines
University Hospital Inselspital, Berne

Terminated

HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt. (HDMM)

AML, Adult

Switzerland
VitNovo, Inc.

Completed

DCB-DM101 in Healthy Volunteers and for Type 2 Diabetes Mellitus Patients

Type2 Diabetes

Taiwan
Prestige Biopharma Limited

Completed

A Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD201 and EU-Herceptin® and US-Herceptin® in Healthy Male Subjects (TROIKA-1)

Healthy Volunteers

Australia
Novartis Pharmaceuticals

Active, not recruiting

A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.

Acute Myeloid Leukemia

Italy, Hong Kong, Israel, Hungary, Turkey, Malaysia, United States
Kitasato University
Aetas Pharma Co. Ltd.

Unknown

First-in-Patient Study for Sing le Dose of M201-A Hydrochloride Injection in Japanese Patients With Paroxysmal Atrial Fibrillation

Paroxysmal Atrial Fibrillation

Japan
Hanwha Chemical

Completed

Safety and Pharmacokinetic Characteristics of HD203 in Healthy Male Volunteers (SPH)

Healthy

Korea, Republic of
Centre Leon Berard

Recruiting

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST)

Malignant Solid Tumor

France
Abbott

Terminated

Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)

Ulcerative Colitis

United States, Canada, Croatia, Italy, Russian Federation, Spain
Yuji KUMAGAI
Aetas Pharma Co. Ltd.

Completed

First-in-Human Dose Escalation Study of M201-A in Healthy Japanese Subjects

Healthy Volunteers

Japan
Kitasato University
Aetas Pharma Co. Ltd.

Completed

Multiple Dose Escalation Study of M201-A in Healthy Japanese Subjects

Healthy Volunteers

Japan
PDL BioPharma, Inc.

Terminated

An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis

Ulcerative Colitis

Belgium, France, United States, Italy, Australia, Czech Republic, Netherlands, Ireland, Norway, Canada, Austria, Germany, Hungary, Ukraine
Facet Biotech
PDL BioPharma, Inc.

Withdrawn

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Intravenous Steroid-Refractory Ulcerative Colitis
Vical

Completed

Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults

Genital Herpes Simplex Type 2

United States
Novartis Pharmaceuticals

Completed

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

United States, Spain, Taiwan, Germany, Netherlands, United Kingdom, Korea, Republic of
Syneos Health
Himuka AM Pharma Corp.

Recruiting

Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201

Crohn's Disease | Ulcerative Colitis

Australia
Assembly Biosciences

Terminated

ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis

Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic Mild

United States, Canada
Prestige Biopharma Limited

Completed

To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects

Healthy Volunteers

New Zealand
Shanghai Synergy Pharmaceutical Sciences Co., Ltd.

Not yet recruiting

A Single Dose Escalation Study of HHT201 in Healthy Subjects

Alzheimer Disease

China
Shanghai Synergy Pharmaceutical Sciences Co., Ltd.

Completed

Safety and Pharmacokinetic of Donepezil Pamoate in Healthy Subjects

AD

China
TransDerm, Inc.
Pachyonychia Congenita Project

Completed

Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)

Pachyonychia Congenita

United States
Hanwha Chemical

Completed

Safety and Pharmacokinetic Characteristics of HD203 Liq. in Healthy Subjects

Healthy

Korea, Republic of
Prestige Biopharma Limited

Completed

A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients (TROIKA)

HER2 Positive Breast Cancer

Spain, Malaysia, Estonia, Hungary, Thailand, Belarus, Bulgaria, France, Georgia, Italy, Poland, Russian Federation, Ukraine
Hanwha Chemical

Completed

Safety and Pharmacokinetic Characteristics of HD203 Liquid in Healthy Male Volunteers

Healthy

Korea, Republic of
BioMAS Ltd

Terminated

Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients

Chemotherapy Induced Thrombocytopenia

Israel
Prestige Biopharma Limited

Active, not recruiting

A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients

Lung Cancer | Non-small Cell Lung Cancer

India, Hungary, Georgia, Philippines, Belarus, Bulgaria, Croatia, Greece, Latvia, Malaysia, Poland, Russian Federation, Serbia, Slovakia, Thailand, Turkey, Ukraine
Feramda

Completed

Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)

Neovascular Age-related Macular Degeneration

Israel
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Locally Advanced Lung Non-Small... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy

Recurrent Brain Neoplasm

United States
Novartis Pharmaceuticals

Withdrawn

HDM201 Added to CT in R/R or Newly Diagnosed AML

Leukemia, Myeloid, Acute
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Recurrent Peritoneal Malignant Mesothelioma | Recurrent Pleural Malignant Mesothelioma | Vaginal Squamous Cell Carcinoma, Not Otherwise Specified | Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor | Recurrent Merkel Cell Carcinoma | Recurrent Nasopharynx Carcinoma | Appendix Adenocarcinoma and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Refractory Melanoma | BRAF V600 Wild Type | Intracranial Melanoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Colorectal Carcinoma | Refractory Colorectal Carcinoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7 | EGFR Exon 19 Deletion Mutation | EGFR NP_005219.2:p.L858R

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type

United States
M.D. Anderson Cancer Center

Recruiting

Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer

Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Resectable Hepatocellular Carcinoma | Stage I Hepatocellular Carcinoma AJCC v8 | Stage IA Hepatocellular Carcinoma AJCC v8

United States
National Cancer Institute (NCI)

Completed

Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Stage IV Cervical Cancer AJCC v6 and v7 | Stage IVB Cervical Cancer AJCC v6 and v7

United States

Search clinical trials for: HDM201

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations